ALTERITY THERAPEUTICS-ADR (ATHE) Fundamental Analysis & Valuation

NASDAQ:ATHE • US02155X2053

Current stock price

3.41 USD
+0.08 (+2.4%)
Last:

This ATHE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ATHE Profitability Analysis

1.1 Basic Checks

  • ATHE had negative earnings in the past year.
  • In the past 5 years ATHE always reported negative net income.
  • In the past 5 years ATHE always reported negative operating cash flow.
ATHE Yearly Net Income VS EBIT VS OCF VS FCFATHE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M

1.2 Ratios

  • With a decent Return On Assets value of -25.63%, ATHE is doing good in the industry, outperforming 71.29% of the companies in the same industry.
  • ATHE has a Return On Equity of -26.89%. This is in the better half of the industry: ATHE outperforms 78.03% of its industry peers.
Industry RankSector Rank
ROA -25.63%
ROE -26.89%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATHE Yearly ROA, ROE, ROICATHE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • ATHE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATHE Yearly Profit, Operating, Gross MarginsATHE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200K -400K -600K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ATHE Health Analysis

2.1 Basic Checks

  • ATHE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for ATHE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ATHE Yearly Shares OutstandingATHE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M
ATHE Yearly Total Debt VS Total AssetsATHE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

2.2 Solvency

  • ATHE has an Altman-Z score of 14.68. This indicates that ATHE is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ATHE (14.68) is better than 86.90% of its industry peers.
  • ATHE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • ATHE has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.68
ROIC/WACCN/A
WACC9.7%
ATHE Yearly LT Debt VS Equity VS FCFATHE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M 30M

2.3 Liquidity

  • ATHE has a Current Ratio of 21.98. This indicates that ATHE is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 21.98, ATHE belongs to the best of the industry, outperforming 96.34% of the companies in the same industry.
  • ATHE has a Quick Ratio of 21.98. This indicates that ATHE is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ATHE (21.98) is better than 96.34% of its industry peers.
Industry RankSector Rank
Current Ratio 21.98
Quick Ratio 21.98
ATHE Yearly Current Assets VS Current LiabilitesATHE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ATHE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 60.00% over the past year.
  • The Revenue has grown by 376.39% in the past year. This is a very strong growth!
  • Measured over the past years, ATHE shows a very strong growth in Revenue. The Revenue has been growing by 92.01% on average per year.
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
Revenue 1Y (TTM)376.39%
Revenue growth 3Y463.07%
Revenue growth 5Y92.01%
Sales Q2Q%717.43%

3.2 Future

  • ATHE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.87% yearly.
  • ATHE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 157.28% yearly.
EPS Next Y-7533.88%
EPS Next 2Y-773.72%
EPS Next 3Y-324.21%
EPS Next 5Y14.87%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y157.28%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ATHE Yearly Revenue VS EstimatesATHE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2029 2030 2031 2032 200M 400M 600M 800M
ATHE Yearly EPS VS EstimatesATHE Yearly EPS VS EstimatesYearly EPS VS Estimates 2026 2027 2028 2029 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

0

4. ATHE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ATHE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATHE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATHE Price Earnings VS Forward Price EarningsATHE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATHE Per share dataATHE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

  • A cheap valuation may be justified as ATHE's earnings are expected to decrease with -324.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-773.72%
EPS Next 3Y-324.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ATHE Dividend Analysis

5.1 Amount

  • ATHE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ATHE Fundamentals: All Metrics, Ratios and Statistics

ALTERITY THERAPEUTICS-ADR

NASDAQ:ATHE (3/25/2026, 8:11:16 PM)

3.41

+0.08 (+2.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)N/A
Inst Owners18.93%
Inst Owner Change-2.86%
Ins Owners1.91%
Ins Owner ChangeN/A
Market Cap61.81M
Revenue(TTM)1.24M
Net Income(TTM)-14.59M
Analysts80
Price Target3.37 (-1.17%)
Short Float %0.11%
Short Ratio1.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.09%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-39.3%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 71.31
P/FCF N/A
P/OCF N/A
P/B 1.64
P/tB 1.64
EV/EBITDA N/A
EPS(TTM)-0.66
EYN/A
EPS(NY)-41.46
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.05
BVpS2.08
TBVpS2.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.63%
ROE -26.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.98
Quick Ratio 21.98
Altman-Z 14.68
F-ScoreN/A
WACC9.7%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)15.55%
Cap/Sales(5y)732.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
EPS Next Y-7533.88%
EPS Next 2Y-773.72%
EPS Next 3Y-324.21%
EPS Next 5Y14.87%
Revenue 1Y (TTM)376.39%
Revenue growth 3Y463.07%
Revenue growth 5Y92.01%
Sales Q2Q%717.43%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y157.28%
EBIT growth 1Y16.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-116.31%
EBIT Next 3Y-53.43%
EBIT Next 5Y37.48%
FCF growth 1Y9.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.16%
OCF growth 3YN/A
OCF growth 5YN/A

ALTERITY THERAPEUTICS-ADR / ATHE Fundamental Analysis FAQ

What is the fundamental rating for ATHE stock?

ChartMill assigns a fundamental rating of 4 / 10 to ATHE.


What is the valuation status of ALTERITY THERAPEUTICS-ADR (ATHE) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALTERITY THERAPEUTICS-ADR (ATHE). This can be considered as Overvalued.


What is the profitability of ATHE stock?

ALTERITY THERAPEUTICS-ADR (ATHE) has a profitability rating of 1 / 10.


What is the expected EPS growth for ALTERITY THERAPEUTICS-ADR (ATHE) stock?

The Earnings per Share (EPS) of ALTERITY THERAPEUTICS-ADR (ATHE) is expected to decline by -7533.88% in the next year.